ONCOMATRYX
Pioneering Tumor Quantum Immunotherapy
Derio, Spain · Founded 2010 · $97.0M raised
- Headquarters
- Derio
- Employees
- 11–50
- Founded
- 2010
- Business Model
- B2B
- Website
- oncomatryx.com
- Total Funding
- $97.0M
- Last Round
- $67.0M Venture RoundMar 2026
- Rounds
- 2
About
ONCOMATRYX is a clinical-stage biopharmaceutical company pioneering Tumor Quantum Immunotherapy by developing antibody-drug conjugates (ADCs) that target the tumor microenvironment. Their lead candidate, OMTX705, has received FDA and AEMPS IND clearance for treating advanced solid tumors by targeting Fibroblast Activation Protein. The company uses AI and quantum computing to assist in ADC design and candidate selection. Based in Derio, Bizkaia, Spain, ONCOMATRYX has raised $67 million to advance its clinical pipeline.
Summary
ONCOMATRYX is a Biotech company based in Derio, Spain, founded in 2010. It has raised $97.0M in total across 2 rounds, most recently a $67.0M Venture Round round in Mar 2026.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...